Clinical Trial Update: Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS® [Phase 4]

View source ↗

Summary

Phase 4 trial update on dapagliflozin for heart failure with reduced ejection fraction evaluating pulmonary artery hemodynamics in patients using CardioMEMS.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Scripps Health | Conditions: Heart Failure, Systolic | Phase 4 | Status: UNKNOWN